benzydamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
3881 642-72-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • benzydamine HCl
  • benzydamine hydrochloride
  • benzydamide
  • benzydamine
  • benzidamine
  • benzindamine
A benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is used to reduce post-surgical and post-traumatic pain and edema and to promote healing. It is also used topically in treatment of RHEUMATIC DISEASES and INFLAMMATION of the mouth and throat.
  • Molecular weight: 309.41
  • Formula: C19H23N3O
  • CLOGP: 4.29
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 30.29
  • ALOGS: -3.80
  • ROTB: 7

Drug dosage:

DoseUnitRoute
0.15 g O
0.15 g R
9 mg O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 87 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.53 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.28 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.80 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.10 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,ALK,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,TTK 46
kinase-selectivity-class AXL 1
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.596 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
rat-kpuu-brain Rat brain Kpuu 0.904 % High 1

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 390.63 44.79 142 8085 37828 90582392
Vaginal flatulence 384.68 44.79 108 8119 12530 90607690
Proctitis 364.56 44.79 108 8119 15151 90605069
Female genital tract fistula 351.96 44.79 109 8118 17759 90602461
Chronic sinusitis 349 44.79 116 8111 23686 90596534
Radiculopathy 344.02 44.79 108 8119 18397 90601823
Vaginal discharge 338.65 44.79 108 8119 19356 90600864
Paraesthesia oral 320.33 44.79 117 8110 31542 90588678
Oral candidiasis 289.49 44.79 112 8115 35343 90584877
Rectal haemorrhage 251.95 44.79 131 8096 82613 90537607
Procedural pain 249.81 44.79 99 8128 33261 90586959
Frequent bowel movements 244.57 44.79 114 8113 56821 90563399
Colitis ulcerative 220.25 44.79 108 8119 60158 90560062
Haematochezia 212.17 44.79 111 8116 70802 90549418
Colitis 210.74 44.79 110 8117 69832 90550388
Constipation 202.98 44.79 182 8045 280213 90340007
Anaemia 172.92 44.79 185 8042 352617 90267603
Weight decreased 143.30 44.79 174 8053 379736 90240484
Mouth ulceration 138.11 44.79 69 8158 39905 90580315
Neutropenic sepsis 132.83 44.79 53 8174 18077 90602143
Skin candida 127.60 44.79 30 8197 1711 90618509
Therapeutic product effect incomplete 124.74 44.79 118 8109 193778 90426442
Abdominal pain 117.39 44.79 161 8066 395560 90224660
Nausea 114.13 44.79 285 7942 1110031 89510189
Erythema 108.15 44.79 118 8109 229128 90391092
Dyspepsia 107.69 44.79 110 8117 198050 90422170
Mucosal inflammation 99.21 44.79 63 8164 57562 90562658
Hypomagnesaemia 84.88 44.79 48 8179 35540 90584680
Pyrexia 72.14 44.79 174 8053 660311 89959909
Colorectal cancer metastatic 69.46 44.79 16 8211 833 90619387
Headache 63.91 44.79 197 8030 862549 89757671
Excessive eye blinking 61.83 44.79 16 8211 1356 90618864
Ejection fraction decreased 61.49 44.79 35 8192 26218 90594002
Diarrhoea 59.22 44.79 203 8024 938987 89681233
Central pain syndrome 56.81 44.79 13 8214 657 90619563
Nervous system disorder 48.46 44.79 28 8199 21565 90598655
Malaise 47.19 44.79 138 8089 585848 90034372
Lymphoedema 45.29 44.79 23 8204 13730 90606490
Intestinal dilatation 45.04 44.79 14 8213 2296 90617924

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutropenic sepsis 65.17 35.28 23 1348 15923 42604041

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vaginal flatulence 390.00 36.06 107 9402 12037 110567753
Macular degeneration 365.83 36.06 116 9393 21543 110558247
Female genital tract fistula 361.79 36.06 108 9401 16411 110563379
Proctitis 354.88 36.06 107 9402 16820 110562970
Vaginal discharge 348.93 36.06 107 9402 17801 110561989
Chronic sinusitis 345.10 36.06 115 9394 24969 110554821
Radiculopathy 340.84 36.06 107 9402 19229 110560561
Paraesthesia oral 315.67 36.06 116 9393 33555 110546235
Oral candidiasis 273.38 36.06 113 9396 44647 110535143
Procedural pain 245.32 36.06 98 9411 35467 110544323
Frequent bowel movements 222.89 36.06 113 9396 71277 110508513
Rectal haemorrhage 213.17 36.06 131 9378 119702 110460088
Constipation 199.16 36.06 196 9313 357590 110222200
Colitis ulcerative 197.42 36.06 107 9402 77256 110502534
Colitis 179.73 36.06 111 9398 102212 110477578
Neutropenic sepsis 172.14 36.06 73 9436 30673 110549117
Haematochezia 167.39 36.06 111 9398 115413 110464377
Mouth ulceration 155.45 36.06 78 9431 48060 110531730
Anaemia 136.28 36.06 199 9310 546887 110032903
Dyspepsia 129.70 36.06 117 9392 190848 110388942
Weight decreased 123.42 36.06 175 9334 467882 110111908
Nausea 122.85 36.06 303 9206 1235387 109344403
Skin candida 115.54 36.06 29 9480 2299 110577491
Therapeutic product effect incomplete 113.93 36.06 117 9392 223688 110356102
Erythema 96.65 36.06 122 9387 291325 110288465
Abdominal pain 92.29 36.06 161 9348 512828 110066962
Mucosal inflammation 90.16 36.06 71 9438 96070 110483720
Pyrexia 81.29 36.06 213 9296 898052 109681738
Headache 78.57 36.06 208 9301 882169 109697621
Hypomagnesaemia 77.79 36.06 54 9455 60316 110519474
Diarrhoea 67.80 36.06 233 9276 1139272 109440518
Colorectal cancer metastatic 60.36 36.06 16 9493 1573 110578217
Central pain syndrome 54.90 36.06 13 9496 807 110578983
Excessive eye blinking 53.21 36.06 15 9494 1855 110577935
Infusion related reaction 52.67 36.06 107 9402 381055 110198735
Hypokalaemia 49.04 36.06 69 9440 182379 110397411
Ejection fraction decreased 49.01 36.06 35 9474 40845 110538945
Lymphoedema 44.68 36.06 23 9486 14906 110564884
Malaise 43.86 36.06 142 9367 671677 109908113
Intestinal dilatation 39.61 36.06 14 9495 3606 110576184
Bleeding time prolonged 39.58 36.06 11 9498 1291 110578499
Nervous system disorder 37.65 36.06 27 9482 31694 110548096
Neuropathy peripheral 37.06 36.06 60 9449 179217 110400573

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A01AD02 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Other agents for local oral treatment
ATC G02CC03 GENITO URINARY SYSTEM AND SEX HORMONES
OTHER GYNECOLOGICALS
OTHER GYNECOLOGICALS
Antiinflammatory products for vaginal administration
ATC M01AX07 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Other antiinflammatory and antirheumatic agents, non-steroids
ATC M02AA05 MUSCULO-SKELETAL SYSTEM
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
Antiinflammatory preparations, non-steroids for topical use
ATC R02AX03 RESPIRATORY SYSTEM
THROAT PREPARATIONS
THROAT PREPARATIONS
Other throat preparations
MeSH PA D000893 Anti-Inflammatory Agents
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:35337 central nervous system stimulant
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35499 hallucinogen
CHEBI has role CHEBI:36333 local anaesthetic

Related Drugs by ATC class:

A01AD Other agents for local oral treatment 5 drugs
acetylsalicylic acidadrenaloneamlexanoxbecaplerminepinephrine
G02CC Antiinflammatory products for vaginal administration 3 drugs
flunoxaprofenibuprofennaproxen
M01AX Other antiinflammatory and antirheumatic agents, non-steroids 13 drugs
azapropazonechondroitin sulfatediacereinfeprazoneglucosaminemorniflumatenabumetoneniflumic acidnimesulideorgoteinoxaceprolproquazone show all 13 →
M02AA Antiinflammatory preparations, non-steroids for topical use 28 drugs
aceclofenacbendazacbufexamacclofezonedexketoprofendiclofenacesflurbiprofenetofenamatefelbinacfentiazacfeprazoneflurbiprofen show all 28 →
R02AX Other throat preparations 2 drugs
flurbiprofenibuprofen

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.78 Basic
pKa2 1.65 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Soluble guanylate cyclase Enzyme EC50 5.99 CHEMBL

External reference:

IDSource
D01410 KEGG_DRUG
132-69-4 SECONDARY_CAS_RN
C0005099 UMLSCUI
CHEBI:94563 CHEBI
CHEMBL12610 ChEMBL_ID
CHEMBL1528134 ChEMBL_ID
DB09084 DRUGBANK_ID
1927 INN_ID
4O21U048EF UNII
12555 PUBCHEM_CID
1425 RXNORM
003474 NDDF
004658 NDDF
331143003 SNOMEDCT_US
350307000 SNOMEDCT_US
421319000 SNOMEDCT_US
D001591 MESH_DESCRIPTOR_UI

Pharmaceutical products:

None